Theseus Pharmaceuticals (THRX) Income Annual - Discounting Cash Flows
Theseus Pharmaceuticals, Inc.
THRX (NASDAQ)

* (except for per share items) of USD
Period Ending: LTM
(Last Twelve Months)
2022
12-31
2021
12-31
2020
12-31
2019
12-31
Report Filing 2023-03-09 2022-03-10 2020-12-31 2019-12-31
Revenue
0.00 0.00 0.00 0.00
Cost of Revenue
0.44 0.00 0.00 0.00
Gross Profit
-0.44 0.00 0.00 0.00
Operating Expenses
53.6 27.3 6.83 4.94
Research & Development
35.7 18.3 5.96 4.12
Selling, General and Administrative
18.4 9.01 0.88 0.82
Other Operating Expenses
-0.44 0.00 0.00 0.00
Operating Income
-54.1 -27.3 -6.84 -4.94
Net Non-Operating Interest
0.00 0.00 0.00 0.00
Interest Income
0.00 0.00 0.00 0.00
Interest Expense
0.00 0.00 0.00 0.00
Equity & Other Income/(Expense)
3.48 0.03 -5.16 -2.24
Income Before Tax
-50.6 -27.3 -12.0 -7.18
Income Tax Expense
-3.53 0.00 0.00 0.00
Income Attributable to Non-Controlling Interest
0.00 0.00 0.00 0.00
Net Income
-47.1 -27.3 -12.0 -7.18
Depreciation and Amortization
0.05 0.00 0.00 0.00
EBITDA
-54.0 -27.3 -6.83 -4.94
Earnings Per Share (EPS)
-1.220 -2.840 -0.470 -0.600
Diluted Earnings Per Share
-1.220 -2.840 -0.470 -0.600
Weighted Average Shares Outstanding
38.5 9.63 25.4 11.9
Diluted Weighted Average Shares Outstanding
38.5 9.63 25.4 11.9
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us